BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 20051371)

  • 1. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer.
    Bailey HH; Kim K; Verma AK; Sielaff K; Larson PO; Snow S; Lenaghan T; Viner JL; Douglas J; Dreckschmidt NE; Hamielec M; Pomplun M; Sharata HH; Puchalsky D; Berg ER; Havighurst TC; Carbone PP
    Cancer Prev Res (Phila); 2010 Jan; 3(1):35-47. PubMed ID: 20051371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity.
    Kreul SM; Havighurst T; Kim K; Mendonça EA; Wood GS; Snow S; Borich A; Verma A; Bailey HH
    Cancer Prev Res (Phila); 2012 Dec; 5(12):1368-74. PubMed ID: 23060038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention.
    Meyskens FL; Gerner EW; Emerson S; Pelot D; Durbin T; Doyle K; Lagerberg W
    J Natl Cancer Inst; 1998 Aug; 90(16):1212-8. PubMed ID: 9719082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
    Carbone PP; Douglas JA; Larson PO; Verma AK; Blair IA; Pomplun M; Tutsch KD
    Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):907-12. PubMed ID: 9796636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer.
    Einspahr JG; Nelson MA; Saboda K; Warneke J; Bowden GT; Alberts DS
    Clin Cancer Res; 2002 Jan; 8(1):149-55. PubMed ID: 11801552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants.
    Carbone PP; Pirsch JD; Thomas JP; Douglas JA; Verma AK; Larson PO; Snow S; Tutsch KD; Pauk D
    Cancer Epidemiol Biomarkers Prev; 2001 Jun; 10(6):657-61. PubMed ID: 11401916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine.
    Love RR; Carbone PP; Verma AK; Gilmore D; Carey P; Tutsch KD; Pomplun M; Wilding G
    J Natl Cancer Inst; 1993 May; 85(9):732-7. PubMed ID: 8478959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ototoxicity of Long-Term α-Difluoromethylornithine for Skin Cancer Prevention.
    Chow CL; Havighurst T; Lozar T; Jones TD; Kim K; Bailey HH
    Laryngoscope; 2023 Mar; 133(3):676-682. PubMed ID: 35620919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the development of metastatic squamous cell carcinoma in protein kinase C epsilon transgenic mice by alpha-difluoromethylornithine accompanied by marked hair follicle degeneration and hair loss.
    Wheeler DL; Ness KJ; Oberley TD; Verma AK
    Cancer Res; 2003 Jun; 63(12):3037-42. PubMed ID: 12810623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251).
    Kadakia KC; Barton DL; Loprinzi CL; Sloan JA; Otley CC; Diekmann BB; Novotny PJ; Alberts SR; Limburg PJ; Pittelkow MR
    Cancer; 2012 Apr; 118(8):2128-37. PubMed ID: 21882176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers.
    Fabian CJ; Kimler BF; Brady DA; Mayo MS; Chang CH; Ferraro JA; Zalles CM; Stanton AL; Masood S; Grizzle WE; Boyd NF; Arneson DW; Johnson KA
    Clin Cancer Res; 2002 Oct; 8(10):3105-17. PubMed ID: 12374678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sun protection for preventing basal cell and squamous cell skin cancers.
    Sánchez G; Nova J; Rodriguez-Hernandez AE; Medina RD; Solorzano-Restrepo C; Gonzalez J; Olmos M; Godfrey K; Arevalo-Rodriguez I
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011161. PubMed ID: 27455163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.
    Elmets CA; Viner JL; Pentland AP; Cantrell W; Lin HY; Bailey H; Kang S; Linden KG; Heffernan M; Duvic M; Richmond E; Elewski BE; Umar A; Bell W; Gordon GB
    J Natl Cancer Inst; 2010 Dec; 102(24):1835-44. PubMed ID: 21115882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-melanoma skin cancer event rates in a formalized clinical trial setting: considerations for clinical trial design.
    Lozar T; Kim K; Havighurst TC; Wood GS; Kolesar JM; Bailey HH
    Eur J Cancer Prev; 2024 Jan; 33(1):69-72. PubMed ID: 37401516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skin cancer chemoprevention: strategies to save our skin.
    Einspahr JG; Bowden GT; Alberts DS
    Recent Results Cancer Res; 2003; 163():151-64; discussion 264-6. PubMed ID: 12903851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients.
    O'Shaughnessy JA; Demers LM; Jones SE; Arseneau J; Khandelwal P; George T; Gersh R; Mauger D; Manni A
    Clin Cancer Res; 1999 Nov; 5(11):3438-44. PubMed ID: 10589756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice.
    Fischer SM; Conti CJ; Viner J; Aldaz CM; Lubet RA
    Carcinogenesis; 2003 May; 24(5):945-52. PubMed ID: 12771040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difluoromethylornithine chemoprevention of epidermal carcinogenesis in K14-HPV16 transgenic mice.
    Arbeit JM; Riley RR; Huey B; Porter C; Kelloff G; Lubet R; Ward JM; Pinkel D
    Cancer Res; 1999 Aug; 59(15):3610-20. PubMed ID: 10446971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of mouse skin tumor promotion and of promoter-stimulated epidermal polyamine biosynthesis by alpha-difluoromethylornithine.
    Takigawa M; Verma AK; Simsiman RC; Boutwell RK
    Cancer Res; 1983 Aug; 43(8):3732-8. PubMed ID: 6407752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of metastatic Lewis lung carcinoma with DL-alpha-difluoromethylornithine.
    Bartholeyns J
    Eur J Cancer Clin Oncol; 1983 Apr; 19(4):567-72. PubMed ID: 6407845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.